{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:44:40Z","timestamp":1791351880937,"version":"4.3.1"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100020453","name":"w. l. gore and associates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To report 1-year outcomes of real-world clinical data from patients with de novo or restenotic iliac artery lesions treated with the GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface (VSX) device.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Devices were implanted to treat de novo atherosclerotic or restenotic iliac artery lesions. The primary endpoint was freedom from device-related serious adverse events (SAEs) at 1 year. Additional endpoints included descriptive analyses and Kaplan-Meier estimates of primary patency, primary-assisted patency, and secondary patency; freedom from major amputation, freedom from target lesion revascularization (fTLR); and changes in Rutherford classification and the Ankle Brachial Index (ABI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The 100 patients were treated, mean age 66.9 years and 75.0% male, had a mean (\u00b1SD) lesion length of 102\u00b160.9 mm and 62.2% were chronic total occlusions; 70.6% were classified as Trans-Atlantic Inter-Society Consensus Document (TASC) C\/D, and 20 lesions were across the inguinal ligament. Maximum stenosis was 88.6\u00b117.9%. Technical success was 100%. At 1 year, there were no device-related deaths, 97.8% of patients were free from device-related SAEs, and 99.0% were free from major amputations. Estimates of lesion primary patency, primary-assisted patency, and secondary patency were 95.0% (confidence interval [CI]=87.1, 98.1), 96.3% (CI=89.0, 98.8), and 97.4% (CI=90.1, 99.4), respectively; fTLR was 96.2% (CI=90.1, 98.5). Patients with restenotic lesions and patients &lt;60 years old had lower primary patency, primary-assisted patency, and fTLR rates. Change from baseline to 1 year in the mean ABI was 0.56\u00b10.17 to 0.88\u00b10.15. The rate of asymptomatic patients (Rutherford 0) was 1.0% at baseline and 63.2% at 1 year; patients with intermittent claudication decreased from 52.0% to 35.1%, and critical limb-threatening ischemia from 37.0% to 1.8%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The European registry 1-year outcomes demonstrated the safety and effectiveness of the VSX device in the treatment of iliac lesions evidenced by high patency, no device-related deaths, and low numbers of major amputation and reintervention procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>\n                      The European registry reflecting a \u2018real-world\u2019 setting of patients treated with the GORE\n                      <jats:sup>\u00ae<\/jats:sup>\n                      VIABAHN\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Endoprosthesis with PROPATEN Bioactive Surface for aortoiliac occlusive disease demonstrated that the self-expanding covered stent was a safe and effective treatment option. At 1 year, 83% of patients had no-to-minimal pain and discomfort and 77% of patients rated no-to-slight mobility impairment issues (5Q-5D-5L assessment). There were no device-related deaths, only 1 amputation, and few reintervention procedures. This study revealed that patients younger than 60 years old or those treated for restenosis had greater risk for target lesion revascularization, device- or limb-related serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028251399582","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:56:18Z","timestamp":1766750178000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["One-Year Clinical Outcomes of a Self-Expanding Covered Stent for Aortoiliac Occlusive Disease"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-1768","authenticated-orcid":false,"given":"Michel M.P.J.","family":"Reijnen","sequence":"first","affiliation":[{"name":"Department of Surgery, Rijnstate Hospital, Arnhem, The Netherlands"},{"name":"Multi-Modality Medical Imaging Group, University of Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mezes","sequence":"additional","affiliation":[{"name":"Department of Radiology, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-7160","authenticated-orcid":false,"given":"Konstantinos","family":"Tigkiropoulos","sequence":"additional","affiliation":[{"name":"Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.12.009"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2023.08.067"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2016.02.064"},{"issue":"2","key":"e_1_3_3_5_2","first-page":"662","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019 Jun;69(6s):3s-125s.e40","volume":"70","author":"Conte MS","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019 Jun;69(6s):3s-125s.e40. J Vasc Surg. 2019;70(2):662.","journal-title":"J Vasc Surg"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx095"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2010.04.080"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.02.005"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0021-9509.17.08303-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2020.01.084"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2024.06.008"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2022.11.008"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.05.015"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602817720463"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820920569"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602816680570"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.29920"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-023-02274-5"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2010.02.032"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.06.097"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.02.055"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1583\/JEVT-12-3941MR.1"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2015.06.112"},{"issue":"2","key":"e_1_3_3_24_2","first-page":"230","article-title":"BeGraft peripheral PMCF Study: 12-month results","volume":"60","author":"Deloose K","year":"2019","unstructured":"Deloose K, Bosiers M, Callaert J, et al. BeGraft peripheral PMCF Study: 12-month results. J Cardiovasc Surg (Torino). 2019;60(2):230\u2013236.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-023-03370-9"},{"issue":"1","key":"e_1_3_3_26_2","article-title":"Heparinised covered stents for external iliac artery occlusive disease: a multicentre retrospective register. Presented at the European Society for Vascular Surgery 38th Annual Meeting; September 24-27, 2024; Krakow","volume":"69","author":"Lebaz-Dubosq M","year":"2025","unstructured":"Lebaz-Dubosq M, Hurtado R, Pruvot L, et al. Heparinised covered stents for external iliac artery occlusive disease: a multicentre retrospective register. Presented at the European Society for Vascular Surgery 38th Annual Meeting; September 24-27, 2024; Krakow. Eur J Vasc Endovasc Surg 2025;69(1):e92-e93.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2024.08.011"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028231166539"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2020.08.139"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251399582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028251399582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251399582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:32:05Z","timestamp":1777498325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028251399582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":28,"alternative-id":["10.1177\/15266028251399582"],"URL":"https:\/\/doi.org\/10.1177\/15266028251399582","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"article-number":"15266028251399582"}}